Development of angiogenesis inhibition as therapy for prostate cancer

ONCOLOGY

Volumn 14, Issue 12 SUPPL. 13, 2000, Pages 21-23

  Daliani, Danai ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ANGIOGENESIS INHIBITOR; ESTRAMUSTINE; PACLITAXEL;

ADJUVANT CHEMOTHERAPY; DRUG EFFECT; HUMAN; MALE; MICROCIRCULATION; PROSTATE TUMOR; REVIEW;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS, ALKYLATING; CHEMOTHERAPY, ADJUVANT; ESTRAMUSTINE; HUMANS; MALE; MICROCIRCULATION; PACLITAXEL; PROSTATIC NEOPLASMS;

EID: 0034574175     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Weidner N, Carroll PR, Flax J, et al: Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol 143:401-409, 1993.
2. Bigler SA, Deering RE, Brawer MK: Comparison of microscopic vascularity in benign and malignant prostate tissue. Hum Pathol 24:220-226, 1993.
3. Brawer MK, Deering RE, Brown M. et al: Predictors of pathologic stage in prostatic carcinoma. The role of neovascularity. Cancer 73(3):678-687, 1994.
4. Siegal JA, Yu E, Brawer MK: Topography of neovascularity in human prostate carcinoma. Cancer 75:2545-2551, 1995.
5. Bostwick DG, Wheeler TM, Blute M, et al: Optimized microvessel density analysis improves prediction of cancer, stage from prostate needle biopsies. Urology 48:47-57, 1996.
6. Silberman MA, Partin AW, Veltri RW, et al: Tumor angiogenesis correlates with progression after radical prostatectomy but not with pathologic stage in Gleason sum 5 to 7 adenocarcinoma of the prostate. Cancer 79:772-779, 1997.
7. Partin AW, Yoo J, Carter B, et al: The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol 150:110-114, 1993.
8. Stamey TA, McNeal JE: Adenocarcinoma of the prostate, in Walsh PC, Retik AB, Stamey MA, et al (eds): Campbell's Urology, 6th ed, pp 1159-1221. Philadelphia, Saunders, 1992.
9. Bolla M, Gonzales D, Warde P, et al: Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 337:295-300, 1997.
10. Pipelich MV, Caplan R, Byhardt RW, et al: Phase III trial of androgen suppression using goserelin in unfavorable prognosis carcinoma of the prostate treated with definitive radiotherapy: Report of Radiation Therapy Oncology Group Protocol 85-31. J Clin Oncol 15:1013-1021, 1997.
11. Daliani D, Finn L, Hodges S, et al: Interleukin-6 (IL-6): a marker of androgen-independent (AI) growth in prostatic carcinoma (PC) (abstract 1183). Proc Am Soc Clin Oncol 16:331a, 1997.
12. Greene GF, Kitadai Y, Pettaway CA, et al: Correlation of metastasis-related gene expression with metastatic potential in human prostate carcinoma cells implanted in nude mice using an in situ messenger RNA hybridization technique. Am J Pathol 150:1571-1582, 1997.